Assenagon Asset Management S.A. Raises Stock Position in Elevance Health, Inc. $ELV

Assenagon Asset Management S.A. lifted its stake in Elevance Health, Inc. (NYSE:ELV) by 17.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 529,508 shares of the company’s stock after purchasing an additional 76,970 shares during the period. Assenagon Asset Management S.A. owned 0.24% of Elevance Health worth $185,619,000 as of its most recent SEC filing.

A number of other large investors have also recently modified their holdings of ELV. Nilsine Partners LLC raised its stake in Elevance Health by 1.5% in the third quarter. Nilsine Partners LLC now owns 1,918 shares of the company’s stock worth $620,000 after buying an additional 29 shares in the last quarter. Sound View Wealth Advisors Group LLC grew its holdings in shares of Elevance Health by 3.0% during the 4th quarter. Sound View Wealth Advisors Group LLC now owns 1,011 shares of the company’s stock worth $354,000 after acquiring an additional 29 shares during the period. HBK Sorce Advisory LLC grew its holdings in shares of Elevance Health by 4.4% during the 3rd quarter. HBK Sorce Advisory LLC now owns 743 shares of the company’s stock worth $260,000 after acquiring an additional 31 shares during the period. Detalus Advisors LLC raised its position in shares of Elevance Health by 1.8% in the 3rd quarter. Detalus Advisors LLC now owns 1,726 shares of the company’s stock worth $558,000 after acquiring an additional 31 shares in the last quarter. Finally, Forum Financial Management LP raised its position in shares of Elevance Health by 1.1% in the 3rd quarter. Forum Financial Management LP now owns 2,971 shares of the company’s stock worth $960,000 after acquiring an additional 33 shares in the last quarter. Institutional investors own 89.24% of the company’s stock.

Elevance Health Stock Down 0.7%

Shares of NYSE:ELV opened at $289.58 on Tuesday. The company has a current ratio of 1.54, a quick ratio of 1.54 and a debt-to-equity ratio of 0.70. The stock has a fifty day simple moving average of $328.88 and a two-hundred day simple moving average of $333.44. Elevance Health, Inc. has a 12-month low of $273.71 and a 12-month high of $458.75. The stock has a market capitalization of $63.91 billion, a price-to-earnings ratio of 11.53, a PEG ratio of 1.60 and a beta of 0.51.

Elevance Health (NYSE:ELV) last released its earnings results on Wednesday, January 28th. The company reported $3.33 EPS for the quarter, topping analysts’ consensus estimates of $3.10 by $0.23. Elevance Health had a return on equity of 15.59% and a net margin of 2.84%.The firm had revenue of $49.31 billion for the quarter, compared to analysts’ expectations of $49.52 billion. During the same period in the prior year, the firm posted $3.84 earnings per share. The company’s quarterly revenue was up 9.6% on a year-over-year basis. Elevance Health has set its FY 2026 guidance at 25.500- EPS. On average, research analysts anticipate that Elevance Health, Inc. will post 33.96 earnings per share for the current fiscal year.

Elevance Health Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, March 25th. Investors of record on Tuesday, March 10th will be given a dividend of $1.72 per share. This is a positive change from Elevance Health’s previous quarterly dividend of $1.71. The ex-dividend date of this dividend is Tuesday, March 10th. This represents a $6.88 annualized dividend and a yield of 2.4%. Elevance Health’s payout ratio is currently 27.39%.

Analyst Ratings Changes

Several research firms recently weighed in on ELV. Wells Fargo & Company dropped their price target on Elevance Health from $424.00 to $391.00 and set an “overweight” rating on the stock in a research report on Friday, January 30th. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and issued a $332.00 price objective on shares of Elevance Health in a report on Thursday, January 29th. JPMorgan Chase & Co. boosted their target price on shares of Elevance Health from $394.00 to $397.00 and gave the company an “overweight” rating in a report on Monday, February 2nd. Jefferies Financial Group reduced their target price on shares of Elevance Health from $401.00 to $395.00 and set a “buy” rating on the stock in a research report on Friday, January 30th. Finally, Sanford C. Bernstein decreased their price target on shares of Elevance Health from $431.00 to $409.00 and set an “outperform” rating for the company in a research note on Friday, January 30th. Twelve investment analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $387.40.

Elevance Health Company Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.